

2. Carpenter CL, ~~XXXX~~ RWK %~~SHU~~ .5 ~~RKHQ~~ % 6FK~~KNHQ~~ %6 ~~QWOH~~\~~SKLFWLRQ~~ QG characterization of phosphoinositide 3-kinase from rat OLYHU-%LRO~~KHP~~
3. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and WKHU~~SHX~~WLFWDJHWLQJ1~~D~~5HY~~QFHU~~
4. ~~QQHPQQ~~ 1 ~~DW~~ -5 8HQR / ~~RJW~~ 3. 3KRVS~~KDLQ~~LQRVLRWRO EVSKRVSK~~D~~HVSHFL~~F~~\$ LV RQFRJHQLF,QW-FQFHU
5. ~~LOHV~~2VW~~NR~~OLQL~~D~~HWD3KRVS~~KDLQ~~LQRVLRWRO NQ~~D~~HVWU~~KW~~XHQ~~Q~~SHUVVLRQRIWKH~~N~~D~~W~~LF V~~Q~~LW~~KOO~~
6. 6WHSKH~~Q~~HUVVRQ . 6WRNH 'HW D 3URWHLQ kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein NQ~~D~~H%6FLHQFH
7. 3RWW~~SHUPX~~W UHJ~~D~~HV JURZWKE GUHF~~W~~SKRVSKRUQ~~D~~LQJ7VF1~~D~~ ~~KOO~~%LRO 658-665.
8. (~~QHU~~ 0~~Ku~~HRQ~~D~~~~K~~KNQ,3, 3 (QJ~~D~~HPHQW 5HWVULFWV ~~N~~ FWLYLW\WR ~~KOO~~D Membranes. Mol Cell 65 (2017): 416-431. ~~QJ~~ ~~Q~~FL~~D~~R /6SDM ~~SHU~~WLQ \$ mTOR-dependent cell survival mechanisms. Cold Spring Harb Perspect Biol 4 (2012).
10. 6~~QJ~~)HUQ~~D~~LHJHO5HW~~D~~ORD~~D~~QFHU6W~~D~~LVVWLFV 2%2~~Q~~VWLP~~D~~HVRI,QFL~~H~~QFH~~Q~~RUWDLW\ :RUOZ~~L~~HIRU~~D~~QFHUVLQR~~Q~~WULHVV~~Q~~FHU- Q~~LQ~~
11. (QJHOP~~D~~ -\$DJHWLQJ 3. VLJQ~~D~~DOLQJ LQ FQFHU RSSRUW~~Q~~LWLHVFKDOHQJHV~~Q~~DLPLW~~D~~LRQV1~~D~~5HY~~QFHU~~
12. :ULJK~~W~~LOHYVN16HUU~~D~~BR~~Q~~- (LFKKRUQ PJA. Mechanisms of Resistance to PI3K Inhibitors LQ ~~Q~~FHU ~~D~~WLYH 5HVS~~RQ~~VHV UK7ROHU~~Q~~FH ~~Q~~G Cellular Plasticity. Cancers (Basel) 13 (2021).
13. LP (0HWJHU)LOKR2:LQHU(37KH~~Q~~W~~K~~DKLVWRU\ of hormone receptor-positive breast cancer. Oncology :LOOLVWRQ3~~DN~~
14. HPSHO '(~~QHU~~) ~~DJ~~ \$HW D 5HDZRUO~~Q~~D QD~~V~~LV RI QH~~W~~ JHQHU~~D~~LRQ VHT~~H~~QFLQJ ~~Q~~GSURWHL~~Q~~WKH%LRORJL~~F~~DR~~Q~~VHT~~H~~QFHV~~Q~~DLQFLD6LJQL~~F~~QFHRI H~~SHU~~VVLRQLQPHW~~D~~WLF~~E~~H~~D~~W~~F~~QFHU~~D~~WLHQVW6~~F~~,~~SHU~~VVLRQV%LRPROHF~~SHV~~
15. Alqahtani A ~~HVK~~6. ~~DZQ~~L-~~B~~,~~SHQ~~H 0~~W~~DLRQV LQ 6ROL~~G~~DLJQ~~F~~LHV \$~~V~~RFL~~D~~LRQ ZLWK~~Q~~W~~D~~LRQV1~~D~~W~~R~~PP~~Q~~ Clinicopathological Parameters and Prognosis. Cancers %~~DHO~~
16. ORRQ ~~K~~LQ6.LP.HWD(5~~Q~~2,~~SH~~ H~~SHU~~VVLRQ~~Q~~G,~~SHU~~VVLRQLQGVWDH~~W~~U~~B~~H~~S~~WLF bile duct carcinoma. Pathology 48 (2016): 35-40.
17. Mosele F, Stefanovska B, Lusque A, et al. Outcome and PROHF~~D~~ O~~Q~~Q~~F~~SH RI ~~D~~WLHQVW ZLWK 3,~~SHU~~VVHG PHW~~D~~W~~D~~LF~~E~~H~~D~~W~~F~~QFHU~~Q~~Q2QFRO2u-(~~K~~6R~~F~~OHG Oncol 31 (2020): 377-386.
18. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004): 554. ~~Q~~Qp)~~K~~UMORV(5~~K~~YV~~H~~W~~D~~SSHOLVLERU PIK3CA-Mutated, Hormone Receptor-Positive Advanced %U~~H~~D~~W~~Q~~F~~HU1(QJO-0HG
20. 5~~R~~ 6~~HU~~HR~~N~~V)~~K~~UMORV(HW~~D~~SSHOLVLSOX fulvestrant in PIK3CA-mutated, hormone receptor-SRVLWLYH~~SHU~~VV~~F~~QFHU~~D~~WHU~~N~~QKLEWRU (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol 22 (2021):
21. Pathmanathan Rajadurai, Tatiana Semiglazova, Alinta HJP~~Q~~(~~D~~6~~Q~~QWRQLR %U~~H~~D~~W~~Q~~F~~HU 6PSRVL~~K~~ ,Q 3,~~SH~~JLVWU\ \$1RQLQWHUYHQWLRQ~~D~~ H~~V~~FULSWLYH 5HWURVSHFWLYH ~~R~~KRUW 6W~~X~~ F 3,~~SHU~~VVLRQV LQ 3~~D~~WLHQVW ZLWK RUPRQH 5HFHSWRU 3RVLWLYH 5 ~~Q~~ (SLHUP~~D~~ URZWK)~~B~~WRU 5HFHSWRU 1HJ~~D~~LYH(5~~SHU~~VV~~F~~QFHU~~D~~U~~H~~D~~W~~Q~~F~~HU (ABC) (2021): P5-13-25.
22. :~~D~~NU (~~B~~HULVLF 2 5LH~~Q~~WHSKHQV /:LOOL~~D~~V RL. Structural insights into phosphoinositide 3-kinase F~~D~~V~~L~~V~~Q~~GLJQ~~D~~OLQJ1~~D~~W~~KH~~
23. Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol 347 (2010): 21-41.
24. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase LQ~~SH~~JDQ RI ~~Q~~FWLRQ ~~Q~~HUHQW PHFKQLVPV 3URF 1~~W~~OF~~F~~L86\$
25. ~~D~~DD '3KLOOLSV :~~R~~L63,~~SHU~~VVLRQV LQ ~~E~~H~~D~~W~~F~~QFHU UHFRQFLOLQJ~~Q~~Q~~Q~~JV IURP SUHFOLQL~~F~~D~~Q~~ clinical data. Breast Cancer Res 16 (2014): 201.
26. 0LWFKH~~Q~~LOOLSV :~~R~~XH0R~~H~~OVIRU(\$ORULQJ LQ~~W~~KH%LRORJL~~F~~DR~~Q~~VHT~~H~~QFHV~~Q~~DLQFLD6LJQL~~F~~QFHRI H~~SHU~~VVLRQV%LRPROHF~~SHV~~
27. :X ;5HQXH66~~K~~MUNH1\$HW DFWLY~~D~~LRQ RI GYHUVH VLJQ~~D~~DOLQJ ~~S~~WKZ~~D~~ERQFRJHQLF 3,~~SHU~~VVLRQV1~~D~~W~~R~~PP~~Q~~
28. Janku F, Wheler J-1DQJ\$HW~~D~~3,~~SHU~~VVLRQV

- in advanced cancers: characteristics and outcomes. *Oncotarget* 3 (2012): 1566-1575.
29. López-Knowles E, Segal C V, Gao Q, et al. Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition. *Breast Cancer Res* 16 (2014): R68.
30. Krygowska AA, Castellano E. PI3K: A Crucial Piece in the RAS Signaling Puzzle. *Cold Spring Harb Perspect Med* 8 (2018).
31. Vasan N, Razavi P, Johnson JL, et al. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K α inhibitors. *Science* 366 (2019): 714-723.
32. Martínez-Sáez, O., Chic, N., Pascual, T. et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. *Breast Cancer Res* 22 45 (2020).